280 Shares in Cencora, Inc. (NYSE:COR) Purchased by MCF Advisors LLC

MCF Advisors LLC acquired a new position in Cencora, Inc. (NYSE:COR) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 280 shares of the company’s stock, valued at approximately $68,000.

Several other institutional investors also recently modified their holdings of COR. Occidental Asset Management LLC bought a new position in Cencora in the first quarter worth $3,599,000. Kathmere Capital Management LLC lifted its holdings in shares of Cencora by 15.2% during the 1st quarter. Kathmere Capital Management LLC now owns 1,498 shares of the company’s stock worth $364,000 after acquiring an additional 198 shares during the period. Sawyer & Company Inc bought a new stake in Cencora in the first quarter valued at about $3,354,000. Stillwater Capital Advisors LLC acquired a new position in Cencora in the first quarter worth about $300,000. Finally, Atwater Malick LLC bought a new position in Cencora during the first quarter worth about $927,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on COR shares. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Citigroup boosted their target price on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Robert W. Baird increased their target price on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Finally, SVB Leerink restated an “outperform” rating and issued a $275.00 price target on shares of Cencora in a research report on Thursday. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $235.30.

Cencora Trading Down 1.2 %

COR opened at $225.30 on Friday. Cencora, Inc. has a 1-year low of $171.65 and a 1-year high of $246.75. The stock has a market capitalization of $44.94 billion, a PE ratio of 24.65, a PEG ratio of 1.58 and a beta of 0.48. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. The firm has a 50-day moving average price of $229.12 and a two-hundred day moving average price of $227.99.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The business had revenue of $68.41 billion during the quarter, compared to analyst estimates of $70.60 billion. During the same quarter last year, the business posted $3.50 earnings per share. Cencora’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, equities analysts anticipate that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were issued a dividend of $0.51 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 annualized dividend and a yield of 0.91%. Cencora’s dividend payout ratio is currently 22.32%.

Insider Buying and Selling at Cencora

In other news, CEO Steven H. Collis sold 10,754 shares of Cencora stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total transaction of $2,553,859.92. Following the completion of the sale, the chief executive officer now owns 285,088 shares in the company, valued at approximately $67,702,698.24. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Cencora news, EVP Gina Clark sold 1,874 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $223.86, for a total transaction of $419,513.64. Following the transaction, the executive vice president now owns 13,284 shares in the company, valued at $2,973,756.24. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Steven H. Collis sold 10,754 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $67,702,698.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,956,675 shares of company stock worth $422,352,056. Company insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.